Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study

Beatrice Albanesi; Alessandro Godono; Rosanna Irene Comoretto; Elena Casabona; Giuliano Curoso; Massimiliano Victor Leone; Nicolò Milanesio; Ilenia Mirra; Giulia Montrucchio; Fabrizia Pittaluga; Rossana Cavallo; Marco Clari; Catalina Ciocan

doi:10.3390/vaccines10081241

Vaccines (Aug 2022)

Immune Response of a Heterologous mRNA-1273 Second-Dose Immunization after a First Dose of ChadOx1 against SARS-CoV-2: A Cross-Sectional Study

Beatrice Albanesi,
Alessandro Godono,
Rosanna Irene Comoretto,
Elena Casabona,
Giuliano Curoso,
Massimiliano Victor Leone,
Nicolò Milanesio,
Ilenia Mirra,
Giulia Montrucchio,
Fabrizia Pittaluga,
Rossana Cavallo,
Marco Clari,
Catalina Ciocan

Affiliations

Beatrice Albanesi: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Alessandro Godono: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Rosanna Irene Comoretto: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Elena Casabona: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Giuliano Curoso: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Massimiliano Victor Leone: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Nicolò Milanesio: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Ilenia Mirra: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Giulia Montrucchio: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Fabrizia Pittaluga: Microbiology and Virology Unit, Città della Salute e della Scienza di Torino University Hospital, 10126 Turin, Italy
Rossana Cavallo: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Marco Clari: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy
Catalina Ciocan: Department of Public Health and Pediatrics, University of Torino, 10126 Turin, Italy

DOI: https://doi.org/10.3390/vaccines10081241
Journal volume & issue: Vol. 10, no. 8
p. 1241

Abstract

Read online

Heterologous vaccination regimens could contribute to broadening vaccination coverage. To date, there is little evidence on the effectiveness of a combination of adenoviral COVID-19 vaccines with a second dose of mRNA vaccines. This study aims to evaluate the antibody response to the SARS-CoV-2 spike protein 25 weeks after vaccination with mRNA-1273 after a first dose of ChAdOx1. A cross-sectional study was conducted collecting sociodemographic data, clinical characteristics, and serological data from among the general population. Antibody levels were expressed as binding antibody units (BAU) per mL (cutoff = 33.8 BAU/mL). Linear regression models were used to assess the relationship between the subjects’ characteristics and anti-SARS-CoV-2 antibody levels. A total of 229 participants were followed up after a median time of 173 days. The overall anti-SARS-CoV-2 IgG antibody titer was 729.0 BAU/mL. The multivariable analysis showed that the only factor associated with anti-SARS-CoV-2 IgG levels was the BMI (p = 0.007), with decreases within the healthy range weight and increases in under- or overweight people. Our results support the use of heterologous COVID-19 vaccination regimens, as they can guarantee a sustained immune antibody response. More studies are needed to understand the link between BMI and body composition and the immune response to COVID-19 vaccinations.

Published in Vaccines

ISSN: 2076-393X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine
Website: http://www.mdpi.com/journal/vaccines

About the journal

Abstract

Keywords